M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial☆☆☆
Marc A. Pfeffer,Michael J. Domanski,Joel Verter,Mark Dunlap,Greg C. Flaker,Bernard J. Gersh,Judith Hsia,A. David Goldberg,Marian C. Limacher,Aldo P. Maggioni,Yves Rosenberg,Jean L. Rouleau,J. Wayne Warnica,Alan G. Wasserman,Eugene Braunwald +14 more
TL;DR: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial is studied.
Journal ArticleDOI
Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation
João Pedro Ferreira,Nicolas Girerd,John Gregson,Ichraq Latar,Abhinav Sharma,Marc A. Pfeffer,John J.V. McMurray,Azmil H. Abdul-Rahim,Bertram Pitt,Kenneth Dickstein,Patrick Rossignol,Faiez Zannad +11 more
TL;DR: Readily accessible risk factors associated with the occurrence of stroke were identified and incorporated in an easy-to-use risk score that may help in the identification of patients with MI and HF and a high risk for stroke despite their not presenting with AF.
Journal ArticleDOI
Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.
Roberto S. Kalil,Myra A. Carpenter,Anastasia Ivanova,Lisa Gravens-Mueller,Alin A. John,Matthew R. Weir,Todd E. Pesavento,Andrew G. Bostom,Marc A. Pfeffer,Lawrence G. Hunsicker +9 more
TL;DR: Following kidney transplantation, uric acid concentrations are not independently associated with CV events, mortality, or transplant failure, and the strong association between uric Acid concentrations with traditional risk factors and eGFR is a possible explanation.
Journal ArticleDOI
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
Jean-Claude Tardif,Marie-Pierre Dubé,Marc A. Pfeffer,David D. Waters,Wolfgang Koenig,Aldo P. Maggioni,John J.V. McMurray,Vincent Mooser,Harvey D. White,Therese Heinonen,Donald M. Black,Marie-Claude Guertin,dal-GenE Investigators +12 more
TL;DR: The dal-GenE clinical outcome trial as discussed by the authors was designed to evaluate the effect of the cholesteryl ester transfer protein (CETP) modulator dalcetrapib on the composite of cardiovascular death, myocardial infarction or stroke.